BioCity, a prominent incubator in the life sciences sector, has recently announced its strategic investment in INCUS Performance, underscoring its dedication to nurturing groundbreaking ventures. This move highlights BioCity's ongoing commitment to supporting innovative companies that push the boundaries of technology and science.

Established in 2016, INCUS Performance is a pioneering sports technology start-up focused on revolutionizing athletic training through advanced data analytics. Their innovative platform is designed to enhance training techniques, particularly in swimming and triathlon sports, by leveraging artificial intelligence and data analytics integrated with wearable technology. This approach provides athletes with unparalleled technical insights in an accessible format.

The core of INCUS's offering is the INCUS | NOVA wearable device, which captures detailed motion and technique data during training sessions. This data is automatically processed and presented through a companion app, delivering valuable insights to athletes and coaches. These insights are crucial for optimizing training regimens and employing predictive analytics to inform future strategies.

The INCUS system comprises a wearable device, sophisticated data analytics, and a mobile platform, all meticulously designed to maximize the efficiency of data capture, analysis, and feedback. The system's accuracy and reliability have been validated against gold standard techniques and tested with elite athletes at Loughborough University, a globally recognized sports institution.

BioCity's Strategic Investment

This investment represents BioCity's 27th venture, made in collaboration with co-investors through the BioCity Investment Platform. This platform provides high-net-worth and sophisticated investors with life science expertise access to co-investment opportunities. BioCity's rigorous due diligence process ensures the selection of ventures with substantial growth potential.

Claire Brown, BioCity's Director of Investment, commented, “INCUS Performance addresses a significant gap in the market. Their system's application in swimming shows great promise for triathlon sports. We focus on early-stage ventures to support their growth and facilitate subsequent investment rounds. Chris and the INCUS team exemplify the synergy of commercial and technical expertise.”

Chris Ruddock, Managing Director of INCUS Performance, expressed, “This investment allows us to expand our innovation team, commercialize next-generation wearable technology, and develop further disruptive technologies for sports and personal monitoring. BioCity's network and expertise were pivotal in our decision to partner with them.”

Legal and Regional Support

The funding process was facilitated by law firms Shakespeare Martineau, representing INCUS, and MBM Commercial, representing BioCity. Roger Harcourt, a partner at Shakespeare Martineau, highlighted the potential impact of INCUS's product in the sports wearables market, emphasizing the critical role of investor support in driving tech innovation.

Zara Diloo from MBM Commercial underscored the partnership's importance, noting the potential for INCUS to scale its technology and the supportive role of BioCity in fostering high-growth biotech and health sector companies. She expressed enthusiasm about the long-term benefits and global impact of this collaboration.